Chartwell Investment Partners LLC Invests $662,000 in TransMedics Group, Inc. (NASDAQ:TMDX)

Chartwell Investment Partners LLC bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,219 shares of the company’s stock, valued at approximately $662,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Los Angeles Capital Management LLC lifted its stake in shares of TransMedics Group by 16.8% in the third quarter. Los Angeles Capital Management LLC now owns 10,866 shares of the company’s stock worth $1,706,000 after buying an additional 1,559 shares in the last quarter. Montanaro Asset Management Ltd boosted its holdings in TransMedics Group by 12.5% in the third quarter. Montanaro Asset Management Ltd now owns 117,235 shares of the company’s stock worth $18,364,000 after purchasing an additional 12,985 shares during the last quarter. Cahill Wealth Management LLC boosted its holdings in TransMedics Group by 28.4% in the third quarter. Cahill Wealth Management LLC now owns 3,486 shares of the company’s stock worth $547,000 after purchasing an additional 771 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after purchasing an additional 146,115 shares during the last quarter. Finally, Amalgamated Bank boosted its holdings in TransMedics Group by 777.4% in the third quarter. Amalgamated Bank now owns 9,774 shares of the company’s stock worth $1,535,000 after purchasing an additional 8,660 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Insiders Place Their Bets

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $9,457,269.06. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the transaction, the director now directly owns 732 shares of the company’s stock, valued at $61,158.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,958 shares of company stock valued at $5,230,528 in the last three months. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Stock Performance

TMDX opened at $91.41 on Wednesday. The stock has a market capitalization of $3.07 billion, a price-to-earnings ratio of 97.24 and a beta of 2.08. The company has a fifty day moving average of $130.45 and a 200 day moving average of $139.89. TransMedics Group, Inc. has a fifty-two week low of $56.83 and a fifty-two week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business’s revenue was up 63.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.12) earnings per share. As a group, sell-side analysts forecast that TransMedics Group, Inc. will post 1.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TMDX has been the topic of several research reports. Oppenheimer dropped their target price on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a report on Tuesday, October 29th. Robert W. Baird dropped their target price on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, October 29th. Canaccord Genuity Group dropped their target price on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th. Needham & Company LLC dropped their target price on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th. Finally, JPMorgan Chase & Co. decreased their price target on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 29th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $144.80.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.